You might see people wearing orange this week for National Multiple Sclerosis Awareness Week. More than 2 million people suffer from Multiple Sclerosis (MS) around the world.
Fighting a chronic disease often affects the entire family — but for one metro Detroit woman, the battle has become even more personal.
Sherri Muhzer, 43, has been housebound for 11 years due to her condition.
Thousands of people are expected to converge on Belle Isle Saturday, where they will be getting down and dirty … literally … for multiple sclerosis (MS).
Minnesota Wild goaltender doesn’t want to be considered the NHL’s only player with multiple sclerosis, he just wants to be recognized for stopping the puck.
Wayne State University School of Medicine researchers, working with colleagues in Canada, have found that one or more substances produced by a type of immune cell in people with multiple sclerosis may play a role in the disease’s progression. The finding could lead to new targeted therapies for MS treatment.
More than 1,000 people took part in the Multiple Sclerosis walk in downtown Detroit.
Synthetic Biologics Inc. (NYSE Amex: SYN) Thursday announced the release of its investor relations mobile iPhone App, called the “SYN IR” App, now available for free at the Apple App Store on the iPhone or iPad or at http://bit.ly/I9xDpW.
The pharmaceutical startup Synthetic Biologics Inc. (NYSE Amex: SYN) reported a larger loss for the year ended Dec. 31, but also a host of promising operational highlights.
Synthetic Biologics Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and medicines for serious illnesses, announced that patient enrollment has been completed in a Phase II clinical trial evaluating the efficacy and safety of Synthetic Biologics’ proprietary oral formulation of estriol (Trimesta) for the treatment of relapsing-remitting multiple sclerosis.